China Regional Advisory Council

Chair

Zili Li

Vice President, Head of Asia Pacific R&D, Janssen Research & Development

  
Zili oversees all R&D activities within Asia Pacific, leading over 1,400 science professionals dedicated to delivering transformational healthcare innovation across the region. Zili joined Janssen in June 2019 from the FDA where he served as Associate Director for Global Affairs at the Office of Generic Drugs. There he contributed significantly to the expansion of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) to the field of generic drugs, playing a critical role in China’s National Medical Products Administration’s membership in ICH in 2017. Zili is a graduate of Peking Union Medical College and completed his residency training at Johns Hopkins in 2000.
Members
  • Feng Chen

    Professor, Dean, School of Public Health, Nanjing Medical University

  • Xiaoyuan Chen

    Director, GCP Officer, Beijing Tsinghua Changgung Hospital

  • Zhaohua Chen

    Head of Global Climical Data Services, Pfizer China R&D Center

  • Haidong Chi

    CM0, Lilly China

  • Connie Dai

    Vice President, Strategy Innovation and Decision Science, HLT

  • Irene Deng

    Head of Regulatory Affairs, China, Sanofi

  • Jianing Di

    Senior Director, China Compound Team Leader, Janssen China R&D

  • Kai Gao

    Professor, Life Science School, Shanghai University

  • John Gong

    CEO, 3DMed

  • Tong Guo

    CEO, GEM Flower Pharma Tech

  • Jing He

    SVP, Head of China R&D Global Oncology R&D, Astrazeneca

  • Jinjie Hu

    Co-Chair of FDAAA International Network Committee, Senior Consultant, Biologics Consulting Group

  • Amy Jiang

    Head of Quality Office, Harbour Biomed

  • Michael Jiang

    Head of Scientific Relations and Innovation & Business Development, Sanofi

  • Michael Lee

    Vice President, Head of Biometrics, Harbour BioMed

  • Vera Liang

    Director and Global Safety Risk Lead, Safety Surveillance and Risk Management, Pfizer (China) R&D Co., Ltd.

  • Howe Li

    Chairman and CEO, Deltamed Co. Ltd

  • Jintong Li

    Deputy Director of Drug Clinical Trial and Research Center, China-Japan Hospital

  • Mengjuan Li

    HR Head, Asia Pacific R&D and Innovation, Johnson & Johnson

  • Ning Li

    Chief Physician, Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences

  • Shuting Li

    Deputy Director, GCP Alliance, China

  • Daniel Liu

    Chief Science Officer, Beijing Clinical Service Center

  • Jessica Liu

    Vice President, Head of International Business, Tigermed Consulting Co., Ltd

  • Yanfei Liu

    Director of GCP, Fudan University Shanghai Cancer Center

  • Yi Liu

    Head of Clinical Science and Medical Affairs, dMed Biopharmaceutical Co., Ltd

  • Yuwen Liu

    Founding Partner, Bohe Angel Fund

  • Qi Lu

    Director, Ethics Committee Office, Renji Hospital affiliated with Shanghai Jiaotong University School of Medicine

  • Shun Lu

    Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital, Shanghai Jiaotong University

  • Yuan Meng

    Head of Medical Office R&D, I-Mab Biopharma

  • Reako Ren

    Head of SMO Services, WuXi AppTec

  • Gary Wang

    VP, Human Resources, APAC, & Co-Lead Global HR, BeiGene

  • Jin Wang

    Partner, McKinsey & Company

  • Lin Wang

    VP, Leader of Asia Development Center, Takeda

  • Liqun Wang

    CEO, FosunKite

  • Xingli Wang

    Senior Global Program Clinical Head, Global Drug Development , Novartis China

  • Zaiqi Wang

    CEO, InxMed

  • Amy Wu

    HR Leader, MSD China R&D

  • Ning Xu

    Executive Vice President, Head of Clinical Development and Regulatory Affairs, Zai Lab

  • Angela Yan

    Senior Vice President, Regulatory Affairs & Strategy, dMed

  • Charles Yan

    Senior Director, Data Management and Biometric, Shanghai Hengrui Medicine Co, LTD

  • Dina Yang

    Deputy Director, Head of Communications, China Office, Bill & Melinda Gates Foundation

  • Joanna Yang

    Director, Market Access & Pricing Strategy, AstraZeneca China

  • Wendy Yan

    Senior Vice President, Head of Regulatory Affairs, BeiGene (Beijing) Co., Ltd.

  • Ping Zhao

    General Manager, Greater China, Cstone

  • Liping Zhou

    Asia Pacific Quality Assurance Director, MSD

  • Carol Zhu

    Vice President, Portfolio and Project Management, JW Therapeutics